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The effects of the non-steroidal anti-inflammatory drugs (NSAIDs) on bone quantity and 
quality were investigated for years. However, there is lack of information on the impact 
of NSAIDs on the quality of tooth-supporting alveolar bone in absence of periodontal 
inflammation. Thus, the aim of this study was to evaluate histometrically the influence 
of a selective COX-2 NSAID (Meloxicam) on the inter-radicular bone mineral density in 
rats. Forty-nine adult male Wistar rats were randomly divided into four experimental 
groups: Subcutaneous injection of 0.9% sterile saline for 15 days (G1; n=12) and 45 days 
(G2; n=11); and subcutaneous injection of Meloxicam for 15 days (G3; n=13) and 45 days 
(G4; n=13). Mineral density was histometrically determined in the inter-radicular area 
of the 1st mandibular molars and data analysis performed by two-way ANOVA (a=5%). 
Results showed no interaction between time and treatment (p>0.05) and that meloxicam 
did not affect the alveolar bone density. In contrast, it was found that inter-radicular 
alveolar bone density increased with time (91.88±3.08% and 92.86±2.38% for groups 15 
and 45 days, respectively) (p<0.05). Within the limits of this study, daily administration of 
a selective COX-2 inhibitor (Meloxicam) did not affect the quality of the inter-radicular 
alveolar bone in absence of periodontal infection.
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Introduction
Bone tissue is constantly renewed in a synchronized 
process mediated by cytokines and growth factors involved 
in bone resorption and deposition. The understanding of 
the mechanisms involved with bone homeostasis is crucial, 
especially to approach metabolic bone disorders leading to 
bone loss and consequently decreased quality of life (1).
The effects of inflammatory mediators (such as 
prostaglandins) and growth factors on osteoclasts and 
osteoblasts may trigger the start of bone adaptive changes 
in response to mechanical (2) or endocrine signals (2,3). 
Prostaglandins are produced from membrane phospholipids 
by sequential actions of phospholipase A2 (PLA2) and 
cyclooxygenase (COX) (4). 
Two COX isoforms have been identified in human 
tissues: the regulatory COX-1 enzyme (which provides 
homeostatic levels of prostaglandins) and the inducible 
COX-2 (which can be stimulated by inflammation) (4). COX 
inhibitors are known as non-steroidal anti-inflammatory 
drugs (NSAIDs) and for years the effects of these drugs on 
bone quantity and quality have been investigated. Previous 
studies utilizing specific COX-2 inhibitors demonstrate that 
blocking of COX-2 activity may prevent bone resorption 
(1,4,5-7), but it may also delay healing in bone fractures 
(8,9) and during alveolar bone repair in rats (10). 
NSAIDs are drugs able to block the potential co-
stimulation of osteophytogenesis by mediators of 
inflammation (11) and prescribed primarily for chronic 
management of rheumatic conditions. In dentistry, NSAIDs 
are often used to control pain and inflammation after 
several procedures such as tooth extraction, orthodontic 
movement, orthognathic procedures and other oral 
surgeries (10). Among these NSAIDs, Meloxicam is prescribed 
worldwide, due to its analgesic and anti-inflammatory 
actions. Meloxicam, 4-hydroxy-2-methyl-N-(5-methyl-2-
tiazolil)-2H-1,2-benzotiacina-3-carboxamide-1,1-dioxide, 
is a highly specific COX-2 inhibitor and offers high efficiency 
with very few side effects on the gastrointestinal and renal 
systems (6,12). 
Previous animal studies showed that Meloxicam may 
prevent bone loss in experimental periodontitis (6,7,10,13), 
possibly by controlling COX-2 enzyme function, which is 
up-regulated in highly-inflamed periodontal tissues (12). 
Nowadays, it is proposed that alveolar bone quality 
is a critical factor for teeth and dental implant general 
health and long-term stability. Thus, animal models are 
successfully used to assess the impact of systemic conditions 
and hormone replacement therapy on alveolar bone quality 
(14). Because of the lack of information on the impact of 
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NSAIDs on the quality of tooth-supporting alveolar bone 
in absence of periodontal inflammation, the aim of the 
present study was to assess the effect of daily NSAIDs 
administration to the inter-radicular alveolar bone in rats 
by histological analysis. 
Material and Methods
Animals
Forty-nine male Wistar rats (Rattus norvegicus albinus), 
weighing 250-350 g and aged 90 days at the beginning 
of the experiment were used. During the experiment, the 
animals were maintained in plastic cages (4-5 per cage) 
under the same environmental conditions, with solid food 
and water ad libitum throughout the study. The protocol 
was approved by the University of Campinas Institutional 
Animal Care and Use Committee (protocol number 265-2).
Experimental Design
At the study start, the animals were randomly assigned 
to one of the following experimental groups:
Group 1: Daily (1x/day) Subcutaneous injection (SC) of 
sterile saline (1mL/kg) for 15 days (n=12); Group 2: Daily 
(1x/day) SC injection of sterile saline (1mL/kg) for 45 days 
(n=11); Group 3: Daily (1x/day) SC injection of Meloxicam 
(Movatec®, Boehringer Ingelheim do Brasil Química e 
Farmacêutica Ltda., Itapecerica da Serra, SP, Brazil) (3 
mg/kg) (7) for 15 days (n=13); Group 4: Daily (1x/day) SC 
injection of Meloxicam (3 mg/kg) (7) for 45 days (n=13).
Histological Analysis
The animals were euthanized by deep anesthesia after 
the experimental period. The jaws were removed and 
divided at the mandibular symphysis in hemi-mandibles, 
before fixing in 4% neutral formalin (pH 7.2 – 7.4) for 48 
h. Demineralization was performed in a 1:1 solution of 
50% formic acid and 20% sodium citrate (Morse solution) 
for 60 days. Next, the demineralized bone was dehydrated 
in absolute alcohol, diaphanized in xylol and embedded in 
paraffin. Longitudinal serial sections (6 µm) were obtained 
in a mesial-distal direction, and stained with hematoxylin 
and eosin. 
After excluding the first and the last sections in which 
the furcation region was evident, ten equally distant 
sections of each tooth were selected for histomorphometric 
analysis (Fig. 1). Using an image-analysis system (UTHSCSA 
ImageTool 3.0, San Antonio, TX, USA), the percentage 
of mineralized bone (alveolar bone density) in the 
inter-radicular area of the 1st mandibular molar was 
histometrically determined by a blinded and calibrated 
examiner.
Statistical Analysis
Mean values of alveolar bone density were determined 
for each group and the Kolmogorov-Smirnov test was used 
to determine data normality. Next, two-way ANOVA test 
was used to detect differences between groups according 
to time and treatment. All analyses were performed using 
a 5% significance level (α=0.05).
Results
Quantitative data of alveolar bone density determined 
by histomorphometric analyses are in Table 1 and Figure 
2. There were no statistically significant differences 
between time and treatment (p=0.305), assuming that 
the effect of saline and Meloxicam was the same on the 
quality of the inter-radicular alveolar bone at 15 and 
45 days. Interestingly, data analysis showed that inter-
radicular bone density increased with time regardless of 
the treatment group (88.81±3.21%/91.88±3.08% and 
87.78±4.49%/92.86±2.38% for saline and meloxicam 
administration at 15/45 days, respectively) (p<0.001). 
Table 1. Mean and standard deviation (SD) of the percentage of 
alveolar bone density for the control and test groups 
Period (days)
Saline
Mean (SD)
Meloxicam
Mean (SD)
F p*
15 days
88.81% 
(3.21)
87.78% 
(4.49)
45 days
91.88% 
(3.08)
92.86% 
(2.38)
Time 17.582 p<0.001
Treatment 0.000 p=0.983
Time-Treatment 1.074 p=0.305
* Two-way ANOVA.
Figure 1. Photomicrograph showing the inter-radicular region of 
the first mandibular molar where bone density was histometrically 
determined (yellow line). Mineralized regions circumscribed in black 
(original magnification: 6.25×).
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Figure 3 illustrates the histological aspects of bone 
density observed after administration of sterile saline for 
15 days (A) and 45 days (B) and Meloxicam for 15 days 
(C) and 45 days (D). 
Discussion
The present study demonstrated that meloxicam, a 
selective COX-2 inhibitor, did not affect alveolar bone 
density in the inter-radicular area of periodontally healthy 
mandibular 1st molars in rats. We additionally found that, 
regardless of treatment, bone density increased with time. 
Therefore, these findings suggest that, in physiological 
conditions, NSAIDs did not impact the quality of the tooth-
supporting alveolar bone. 
Morton et al. (15) reported that certain NSAID 
classes may have different effect on bone metabolism. 
Selective COX-2 inhibitors may have greater effects on 
bone metabolism, as compared with COX-1 inhibitors, 
since production of prostaglandins in osteoclasts is 
primarily mediated by COX-2 (16). Thus, selective COX-2 
inhibitors have been suggested to reduce bone remodeling 
and resorption, conserving trabecular bone mass and 
Figure 3. Photomicrograph showing bone density after subcutaneous injections of sterile saline for 15 days (A) and 45 days (B) and meloxicam 
for 15 days (C) and 45 days (D).
Figure 2. Percentage of alveolar bone density after subcutaneous 
injections of sterile saline solution (15 days [G1] and 45 days [G2]) 
and meloxicam (15 days [G3] and 45 days [G4]). One asterisk indicate 
statistically significant difference (p<0.05) and two asterisks indicate 
no statistically significant difference (p>0.05).
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architecture (4). Studies with bone marrow cultures from 
COX-2 knockout mice demonstrated a marked decrease 
in osteoclast responses to stimulators of bone resorption 
and that selective COX-2 inhibitors blocked osteoclast 
formation in this system (3).  
The impact of meloxicam administration on the alveolar 
bone loss resulting from experimental periodontitis has 
been previously investigated (6,7) and the results suggested 
that meloxicam may significantly decrease periodontitis-
resulting bone loss; these findings are in line with others 
(1,4,5,13). Fewer renal side effects have been reported for 
meloxicam compared to other NSAIDs (6,12), indicating 
that meloxicam treatment may be used for a longer time 
(17). Interestingly, aspirin was reported to potentiate the 
effect of selective COX-2 inhibitors, acting on prostaglandin 
production (dependent on arachidonic acid), as well as on 
nitric oxide (NO) and nuclear factor kappa-light-chain-
enhancer of activated B (NF-kB) production (independent 
from arachidonic acid) in cells, leading to increased bone 
density at multiple skeletal sites in men and women (5). 
On the other hand, Shen et al. (18) observed that 
short-term administration of selective COX-2 inhibitors 
resulted in suppression of bone formation and increased 
bone resorption in rats. COX-2 function was reported as 
essential for fracture healing, since this enzyme is critically 
involved in bone repair and required for intramembrane 
and endochondral bone formation (8). After continuous 
administration, selective COX-2 inhibitors (meloxicam) 
may negatively influence bone healing in cortical and 
cancellous bone around titanium implants inserted in 
rats (19). In the present study, in both groups, saline and 
meloxicam, there was an increase in alveolar bone density 
with time, indicating that meloxicam alone did not affect 
tooth-supporting bone quality.
The role of vascular endothelial growth factor (VEGF) 
in bone density was investigated during the bone repair. 
VEGF, described as the most important molecule for 
regulating angiogenesis, plays a critical role in bone 
homeostasis (20). VEGF receptor activation induces 
endothelial cell mobilization, recruitment, differentiation 
and proliferation, as well as the enrollment and survival of 
mesenchymal progenitor cells, osteoblasts and osteoclasts 
(21,22). Although systemic therapies with selective COX-
2 inhibitors may affect VEGF expression in rats (13), the 
results of this study showed similar bone repair between 
saline and Meloxicam after 45 days and this finding 
suggests no direct relationship between Meloxicam and 
increased VEGF expression. Thus, the increased bone density 
observed in 45 days compared to 15 days may suggest other 
mechanisms, including those not depending on arachidonic 
acid. However, Arantes et al. (10) reported an alveolar bone 
repair delay following daily administration of meloxicam 
for 7 days after tooth extraction in rats. Taken together, 
these findings suggest that meloxicam may affect bone 
homeostasis in a VEGF-dependent manner, at least in part. 
Irrational use of NSAIDs, selective and nonselective, 
is associated with a range of potential adverse effects, 
including gastric mucosa damages and an increased risk of 
adverse cardiovascular effects. The risk of different events 
depends on the clinical context, medication and dose (23). 
In addition, long-term NSAIDs administration is employed 
for the treatment of specific diseases including, for example, 
the rheumatoid arthritis. In these cases, a secondary 
osteoporosis with bone loss in the joints is easily recognized 
and may increase the risk of fractures and accompanying 
co-morbidities in these subjects (24). Specifically in relation 
to Meloxicam, Bezerra et al. (6) examined the effect of this 
drug on gastric mucosa of rats and found that the dosage 
of up to 3 mg/kg did not produce significant gastric effects. 
Nevertheless, new therapeutic alternatives to the treatment 
of diseases involving bone metabolism like osteoporosis 
has been carried out for years and the phytotherapeutic 
agents showed promising results (25).
Further controlled clinical studies are required to 
evaluate their long-term benefits and to search for 
less harmful alternative therapies (9). In addition, other 
analyses including immunohistochemical and molecular 
biology and other drugs, may be performed to clarify 
the effect of NSAIDs on cell and tissue behavior during 
the process of bone repair, because multiple mechanisms 
(not yet fully elucidated) may be related to inflammation 
and bone resorption and deposition processes, such as 
VEGF expression, receptor activator of nuclear fator kB, 
RANK/RANKL/receptor osteoprotegerin (OPG) and tumor 
necrosis factor (TNF). Thus, knowledge of the behavior and 
mechanisms of selective COX-2 inhibitors is required for 
future clinical applications. 
Within the limits of the present study, it was concluded 
that daily administration of a selective COX-2 inhibitor 
(Meloxicam) did not affect the quality of the inter-radicular 
alveolar bone in absence of periodontal infection. However, 
further pre-clinical and clinical studies should be considered 
in order to determine the relevance of long-term NSAIDs 
administration to the tooth-supporting alveolar bone 
quality and the potential involved mechanisms.
Resumo
Os efeitos dos fármacos anti-inflamatórios não esteroidais (AINEs) 
sobre a quantidade e qualidade óssea tem sido investigados ao longo 
dos anos.Entretanto, há falta de informação sobre o impacto dos AINEs 
na qualidade do osso alveolar de suporte na ausência de inflamação 
periodontal. Assim, o objetivo deste estudo foi avaliar, histometricamente, 
a influência de um AINE seletivo para COX-2 (Meloxicam) na densidade 
mineral óssea inter-radicular em ratos. Quarenta e nove ratos Wistar, 
machos e adultos foram divididos aleatoriamente em quatro grupos 
experimentais: injeções subcutâneas de 0,9% de solução salina estéril 
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por 15 dias (G1, n=12) e 45 dias (G2, n=11); e injeções subcutâneas de 
Meloxicam por 15 (G3, n=13) e 45 dias (G4, n=13). A densidade mineral 
foi determinada histometricamente na área inter-radicular dos primeiros 
molares mandibulares e a análise dos dados realizada por meio de ANOVA 
(a=5%). Os resultados mostraram nenhuma interação entre tempo e 
tratamento (p>0,05) e que o meloxicam não afetou a densidade óssea 
alveolar. Em contraste, foi encontrado que a densidade óssea alveolar 
inter-radicular aumentou ao longo do tempo (91,88±3,08% e 92,86±2,38% 
para os grupos 15 e 45 dias, respectivamente) (p<0,05). Dentro dos limites 
deste estudo, a administração diária de um inibidor seletivo para COX-2 
(Meloxicam) não afetou a qualidade do osso alveolar inter-radicular na 
ausência de infecção periodontal. 
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